The scientists in Augustin's laboratory consequently pursued
preclinical tumor therapy experiments, which were aimed at not just blocking angiogenesis, but to also suppress the production of tumor - promoting growth factors in endothelial cells.
Not exact matches
«We report much higher therapeutic efficacy in
preclinical brain
tumor models using the combination of both
therapies, leading to an increase in median survival,» Lowenstein says.
Jun. 14, 2017 — A PET probe that detects the amino acid glutamine predicts whether
tumors respond to certain targeted
therapies in
preclinical animal models.